The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00768820

Acronym

VCFS

Enrollment

400

Registered

2008-10-08

Start date

2001-05-01

Completion date

2027-08-01

Last updated

2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fragile X Syndrome, Velocardiofacial Syndrome, Williams Syndrome

Keywords

Velocardiofacial syndrome, Williams syndrome, fragile X syndrome, cognitive phenotype, psychiatric phenotype

Brief summary

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Interventions

DRUGmethylphenidate, fluoxetin, risperidone

first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* chromosomal deletion proven by FISH examination

Design outcomes

Primary

Measure	Time frame
Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments	2 years

Countries

Israel

Contacts

CONTACTDoron Gothelf, MD

gothelf@post.tau.ac.il972-03-5302663

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026